EVALUATION OF INTERLEUKIN-6, TNF-ALPHA, AND TGF-BETA LEVELS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Main Article Content
Abstract
Objective: To determine plasma levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β), and to investigate their associations with selected laboratory parameters in patients with chronic lymphocytic leukemia (CLL).
Methods: A cross-sectional descriptive study was conducted in 50 patients with CLL from March 2022 to September 2023 at the National Institute of Hematology and Blood Transfusion. Plasma concentrations of IL-6, TNF-α, and TGF-β were quantified using the sandwich enzyme-linked immunosorbent assay (ELISA) method.
Results: The median plasma concentrations of IL-6, TNF-α, and TGF-β were 5.63 pg/mL, 0.88 pg/mL, and 534.53 pg/mL, respectively. IL-6 levels differed significantly among risk groups (p < 0.05). Plasma IL-6 was negatively correlated with hemoglobin concentration (r = −0.288; p = 0.043) and hematocrit (r = −0.304; p = 0.032). Plasma TGF-β levels showed positive correlations with red blood cell count (r = 0.407; p = 0.003), hemoglobin (r = 0.428; p = 0.002), and hematocrit (r = 0.417; p = 0.003).
Conclusion: The median plasma concentrations of IL-6, TNF-α, and TGF-β were 5.63 pg/mL, 0.884 pg/mL, and 534.53 pg/mL, respectively. IL-6 and TGF-β may play a role in altering selected hematological parameters and glucose levels in patients with CLL.
Article Details
Keywords
Interleukin 6, TNF-alpha, TGF-beta, chronic lymphocytic leukemia (CLL).
References
2. Hassan EA, Abdelhady EA, Abdelsamee HF, El-Razzaz MK (2024). Serum Interleukin 6 (IL-6) as Prognostic Marker in Egyptian CLL patients. International Journal of Hematology-Oncology Stem Cell Research, 18 (2), 140.
3. Ayoub M, Susin SA, Bauvois B (2024). Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link? Cancers, 17 (1), 72.
4. Marquez ME, Sernbo S, Payque E, et al (2022). TGF-β/SMAD pathway is modulated by miR-26b-5p: Another piece in the puzzle of chronic lymphocytic leukemia progression. Cancers, 14 (7), 1676.
5. Hà TTTT, Huân TPC, Huệ TĐT, et al (2022). Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học. Bộ Y tế,
6. Mousa MA-E-HA-E-R, Eweis IEI, Ahmed SS, Gaafar AM (2022). Assessment of IL6 and TNF α in chronic lymphocytic leukemia. International Journal of Medical Arts, 4 (10), 2725-2733.
7. Ferrajoli A, Keating MJ, Manshouri T, et al (2002). The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 100 (4), 1215-1219.
8. Maltezas D, Sarris K, Koulieris E, et al (2012). Increased serum transforming growth factor-beta1 (Tgf-beta1) is related to a better outcome in MM, WM and CLL patients. Blood advances, 120 (21), 4976.
9. Gora-Tybor J, Blonski JZ, Robak T (2003). Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation, 12 (3), 167-171.
10. Areström I, Zuber B, Bengtsson T, Ahlborg N (2012). Measurement of human latent transforming growth factor-β1 using a latency associated protein-reactive ELISA. Journal of Immunological Methods, 379 (1-2), 23-29.
11. DeCoteau JF, Knaus PI, Yankelev H, et al (1997). Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 94 (11), 5877-5881.